Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

If approved, ZAMTO Cell would be the first dual-target CAR-T therapy ... institutions are now working on CAR-T therapies targeting not just B-cell lymphoma but also multiple myeloma and solid ...

Axi-cel, tisa-cel, and brexu-cel were found comparable to other cellular therapy experiences for patients with B-cell ...

or CAR T cell therapy, where a patient's immune cells are taken out, grown and modified to specifically target certain cancers such as the aggressive lymphoma Cannella had. When he was first ...

At MSKCC, they were focused on CD19 as a target of interest as the ... Although various CAR T-cell therapies are approved in lymphoma, leukemia, and multiple myeloma, patient access has been ...

CAR T-cell therapy is an effective treatment for aggressive subtypes of follicular lymphoma, according to a clinical trial published in Nature Medicine. A team led by researchers at Weill Cornell ...

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy ... refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal ...